The blockade of anti-CD200 antibody reduced the number of intra-tumoral MDSCs, restricting PDAC tumor growth and significantly enhancing the anti-tumor efficacy of ICB and anti-PD-1 antibody (92, 93). This evidence concerns the gene CD200 and neoplasm.